Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
She is director of OTC brand marketing at Dr. Reddy's Laboratories.
The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.
Dr. Amy Baxter is founder and CEO of MMJ Labs.
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures
Critics question the FDA's decision to approve OxyContin for children; AstraZeneca temporarily stops to lung-cancer trials; Sanders will oppose Califf's nomination as FDA commissioner
CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen
Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
Walgreen alleges Endo conspired to keep generic Opana ER off the market.
Opioids lacking abuse-foiling technology will remain available.
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
The survey shows the use of stronger-than-morphine painkillers has jumped.
The specialty biopharma firm says it's hiring new commercial managers after a buying spree.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
The bad news: heroin-related deaths inched upwards.
The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.
The reason: opioids.
The $300,000 grant will go towards an abuse-deterrent technology.
FDA feedback will influence a new clinical trial design, but the regulator's recent reaction was a bit of a surprise.
The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.
Purdue Pharma expects the FDA to vote yea or nay on the drug by October.
Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.
A USA today analysis shows Medicare painkiller prescriptions rose 30% between 2007 and 2012.
Express Scripts said that family and internal medicine doctors were the top opioid prescribers between 2011 and 2012.
Orange and Santa Clara counties are suing painkiller makers like Purdue and Endo, a suit akin to deceptive ad cases launched against the tobacco industry.